Baumgartner J D, Glauser M P
Am J Med. 1984 Oct 19;77(4C):54-8.
The safety of ceftriaxone was compared with that of amoxicillin in a randomized study of 91 patients with community-acquired pneumonia. The origin of infection was similar in the two groups. It was proven or probable Streptococcus pneumoniae in 50 percent of the patients and remained uncertain in 40 percent. Ninety percent of the patients who received ceftriaxone were clinically cured compared with 69 percent of those given amoxicillin (p less than 0.05). However, this difference was not apparent among the patients with proven or probable pneumococcal pneumonia. No severe clinical side effects were observed. Cutaneous reactions were more prevalent in the amoxicillin group, whereas mild diarrhea and mucosal candidiasis were more frequent in the ceftriaxone group. Reversible neutropenia was observed in two patients treated with ceftriaxone and none of those treated with amoxicillin.
在一项针对91例社区获得性肺炎患者的随机研究中,对头孢曲松和阿莫西林的安全性进行了比较。两组的感染源相似。50%的患者感染被证实或可能为肺炎链球菌,40%的患者感染情况仍不确定。接受头孢曲松治疗的患者中有90%临床治愈,而接受阿莫西林治疗的患者中这一比例为69%(p<0.05)。然而,在感染被证实或可能为肺炎球菌肺炎的患者中,这种差异并不明显。未观察到严重的临床副作用。皮肤反应在阿莫西林组更为普遍,而轻度腹泻和黏膜念珠菌病在头孢曲松组更为常见。接受头孢曲松治疗的两名患者出现了可逆性中性粒细胞减少,而接受阿莫西林治疗的患者中未出现此类情况。